Improving the effectiveness of treatment for patients with diabetic retinopathy

Authors: Skrypnyk R.1, Skrypnychenko I.1, Dziuba N.2

1 Bogomolets National Medical University, Kyiv, Ukraine
2 Kyiv City Center for the Diagnosis and Treatment of Vascular Dystrophic Eye Diseases, Kyiv, Ukraine

Abstract

Diabetes mellitus is one of the most topical medical and social problems worldwide. Diabetic retinopathy (DR) occupies a special place among vascular complications of the diabetes mellitus. The search for effective pathogenetical treatment for DR stays one of the important tasks of ophthalmology. Meldonium is one of the drugs that has wide range therapeutic effects including systemic metabolic, anti-ischemic and neuroprotective actions. Ripronate inclusion in the complex treatment of patients with nonproliferative and preproliferative stages of DR has a positive effect on the clinical and functional parameters of the organ of vision.

Keywords: diabetes mellitus, diabetic retinopathy, ripronate.

Article in PDF
ARTICLES FROM CATEGORY
Support of educational events. Participation of World Medicine in the First Congress of Optometrists of Ukraine.
Cetirizine is an effective and safe antihistamine (literature review, results of clinical researches)
Опубліковано в журналі «Сучасна педіатрія. Україна» №8 (120) ’2021
All-Ukrainian Scientific and Practical Conference “Aspects of Internal Medicine in Wartime 2024"

PROVE YOU ARE A MEDICAL PROFESSIONAL

Attention: This section is intended for healthcare professionals only. If you are not a medical professional, you can return to the main page by clicking the “No” option

Yes
No

CARD-NOTIFICATION OF AN ADVERSE DRUG REACTION AND/OR LACK OF EFFICACY OF THE MEDICINE

INFORMATION ABOUT THE PATIENT

SUSPECTED AR/LE

Suspected AR (describe each clinical manifestation of the AR with dates and times of onset and end and outcome)/Indication of the LE

INFORMATION ABOUT SUSPECTED MEDICINES

INFORMATION ABOUT RELATED MEDICINES

(with the exception of drugs used to correct the effects of AR/LE)
(concomitant diagnoses, laboratory and instrumental studies, allergy history, pregnancy with gestational age, method of conception, pregnancy outcome (if the pregnancy ended, the date of delivery, type of delivery, etc.)

Information about the messenger

INFORMATION ABOUT THE MEDICAL/PHARMACY SPECIALIST

(if not the notifier)

MESSAGE CARD for the patient

to provide the patient and/or his/her representative with information on adverse drug reactions and/or lack of efficacy of the drug

INFORMATION ABOUT THE PATIENT

Information about the suspected medicine

Information on the prescription of the suspected medicinal product

Information about the messenger

Information about the physician, healthcare facility and place of residence of the patient who had an adverse medicine reaction and/or lack of efficacy of the medicine

розробка сайту Estetic web design